Background Although MELD score is a reliable tool for estimating mortality in the waiting list, criteria for preoperative prediction of survival after liver transplantation (LT) are lacking. ALBI score was validated as a prognostic marker for hepatocellular carcinoma patients undergoing transarterial chemoembolization, hepatic resection, and sorafenib treatment but not for LT outcomes yet. This study aimed to evaluate ALBI score as a prognostic factor in LT. Methods This is a single-center analysis of patients undergoing LT between October 2001 and June 2017. Primary endpoint was overall post-LT mortality. Secondary endpoint was 90-day mortality. Results Of all 301 patients included in this study, 185 (61.5%) were males. The median age was 54.1 ± 11.3 years. Univariate and multivariate analysis revealed that ALBI grade 3 (HR 1.836, 95% CI 1.154-2.921, p = 0.010), low serum albumin (HR 0.628, 95% CI 0.441-0.893, p = 0.010), black race (HR 2.431, 95% CI 1.160-5.092, p = 0.019), and elevated body mass index (HR 1.061, 95% CI 1.022-1.102, p = 0.002) all were associated with decreased overall survival following LT. Patients with both ALBI grade 3 (n = 25) and calculated MELD score ≥ 25 had the lowest overall survival (p < 0.001). Discussion ALBI grade 3 was related to lower post-LT survival and can be utilized as a tool for risk stratification in LT.
Introduction
Liver transplantation (LT) is the standard of care for patients suffering from end-stage liver disease [1, 2] . However, LT outcomes have remained relatively unchanged over the last decade [3] . The Model for End-Stage Liver Disease (MELD) score was designed to optimize organ allocation and reduce mortality in the LT waiting list [3, 4] . Although being able to stratify risk of death from complications related to end-stage liver disease, MELD score has a limited ability to estimate post-LT mortality [5] [6] [7] .
Detection of pre-LT-negative predictors may help finding strategies to protect selected recipients at higher risk of death. It has been reported that poor nutritional status has a negative impact on post-LT outcomes [4, 8] . Recently, the albumin-bilirubin (ALBI) score has been proposed as an inexpensive and simple prognostic marker for patients suffering from hepatocellular carcinoma (HCC) undergoing treatments other than LT [9] . Originally derived from large cohorts of HCC patients and cirrhotic controls, the ALBI score has been validated for HCC patients undergoing transarterial chemoembolization, hepatic resection, and sorafenib treatment [9, 10] . However, the usefulness of the ALBI score as a predictor of post-LT survival was not demonstrated yet. This study aimed to analyze the ALBI score as a predictor of mortality in patients undergoing LT.
Patients and Methods
All consecutive adult patients who underwent first orthotropic LT at our institution between October 2001 and June 2017 were included in this study. Pediatric recipients (aged < 18 years) and recipients of partial grafts (split livers) and grafts from live donors and patients who received simultaneous transplants (e.g., simultaneous liver and kidney transplants) were not included in this analysis. This study complies with ethical standards and was approved by the Institutional Review Board Committee of Hospital de Clinicas de Porto Alegre (Grupo de Pesquisa e Pós-Graduação-GPPG HCPA). This is a retrospective study. Thus, patients were not consented before being included in the study.
All transplants were performed using piggyback technique. Immunosuppression was based on tacrolimus, mycophenolate, and steroids. Induction with basiliximab was provided to patients with kidney failure. Abdominal Doppler ultrasound was performed as periodically in all cases in order to detect liver and vascular complications. Oral feeding was started in the intensive care unit early after extubation. Fresh frozen plasma, cryoprecipitate, and platelets were administered as needed under thromboelastographic guidance.
Primary endpoint was death occurring anytime during post-LT follow-up. Secondary endpoint was mortality occurring during the first 90 post-LT days. Patients were followed until their death or the end of the study period. There were no losses to follow-up during the study period.
The following pre-LT variables were evaluated: age, gender, race composition, body mass index (BMI), history of diabetes mellitus type 2 (DM2), Model for End-Stage Liver Disease (MELD), hepatitis C virus (HCV) status, diagnosis of hepatocellular carcinoma (HCC), serum albumin, serum total bilirubin, International Normalized Ratio (INR), serum sodium, serum creatinine, platelets, platelet/lymphocyte ratio (PLR), neutrophil/lymphocyte ratio (NLR), and albumin-bilirubin (ALBI) score and ALBI grade. The pre-LT laboratory values were measured preferably during the 48 h preceding LT. ALBI score was obtained using the following formula: (log10 bilirubin [μmol/L] × 0.66) + (albumin [g/L] × − 0.085). Based on ALBI score, patients were classified into three groups according to previously defined cutoff values resulting in three grades: ALBI grade 1 (≤ − 2.60), grade 2 (− 2.60 to ≤ − 1.39), and grade 3 (> − 1.39) [11] .
Categorical variables were compared using Chi-square test. Normality test of continuous variables was estimated through the Kolmogorov-Smirnov method. Continuous variables were analyzed with Mann-Whitney U test or T test as appropriate. Univariate analysis was performed through the Cox proportional regression method. For both primary and secondary endpoints, variables that were statistically significant in the univariate analysis (p < 0.05) were pulled into multivariate Cox proportional regression models in order to identify independent risk factors associated with the two study endpoints.
Survival was analyzed using Kaplan-Meier method, and survival comparisons among subgroups were performed using log-rank test. For all analyses, p values < 0.05 were considered as statistically significant. Analyses were performed using SPSS 18.0 for Windows.
Results
A total of 301 patients who underwent first LT were included (Table 1) . Median duration of follow-up was 3520 ± 173 days. Overall, 185 patients (61.5%) were males. Median age was 57 years . The majority of patients were Caucasians (94.7% of patients). Eighty-six patients (28.6%) had a pre-LT history of DM2. The main indication for LT was HCV infection (n = 209, 69.4%), followed by alcohol in 19 patients (6.3%) and hepatitis B virus infection in 13 patients (4.3%). HCC was diagnosed in 150 patients (49.8%). Mean MELD score was 15 [range . For the 151 non-HCC patients, the mean calculated MELD score was 21. For the 150 HCC patients, the mean calculated MELD score was 12. Although patients with HCC were ranked in the LT list based on their appealed artificial MELD score (usually higher than the appealed one), the MELD score reported for HCC patients in this study was the calculated one rather than the appealed one.
Univariate analyses using Cox proportional regressions were performed to identify variables associated with decreased overall post-LT survival ( (Table 4) .
Albumin is part of the ALBI score. Thus, analyzing albumin in a multivariate model in conjunction with ALBI score and/or ALBI grade 3 would lead to a potential for collinearity. Thus, an additional multivariate analysis including albumin (and not including neither ALBI score nor ALBI grade 3), black race, BMI, and MELD score was performed (Table 5 ). Such multivariate analysis revealed only low albumin (HR 0.628, 95% CI 0.441-0.893, p = 0.010) and higher BMI (HR 1.058, 95% CI 1.018-1.098, p = 0.004) as significantly associated with a decreased overall post-LT survival (Table 5) .
MELD score had no prognostic association with post-LT mortality in any of the multivariate models, even after stratifying patients into distinct categories of MELD (Tables 3,  4 , 5).
Receiver operating characteristics (ROC) curves were performed to determine the best variable among the three numeric variables that were independently associated with a decreased overall survival (albumin, BMI, and ALBI score). Among these three variables, ALBI score presented with the highest area under the curve (AUC) ( Table 6 and Fig. 1 ). Presenting an ALBI score of − 1.40 (lowest limit for ALBI grade 3) was associated with a 73.2% specificity, 44.8% sensitivity, a positive predictive value of 46.7%, and a 71.7% negative predictive value for death occurring in the entire follow-up. The accuracy of the point of the test is 63.4%.
Thus, increasing the value of the ALBI score to higher than − 1.40 to encompass the remaining ALBI grade 3 patients would increase the specificity of the test. Thus, 73.2% is the minimal specificity for ALBI grade 3 patients.
Considering the secondary endpoint (death occurring during the first 90 days analyzed using Chi-square test), none of the variables analyzed were associated with decreased survival (Table 7) .
The ability of the ALBI grade to stratify patient survival is displayed in Fig. 2 . Comparison among all three ALBI grades revealed a significant difference in overall survival (p =0.015). ALBI grade 1 (n = 26) was associated with a 1-year survival of 92.3%, 3-, 5-, and 7-year survival of 76.8%. ALBI grade 2 (n = 26) was associated with a 1-year survival of 81.1%, 3-year survival of 74%, 5-year survival of 66.7%, and 7-year survival of 63.4%. ALBI grade 3 (n = 92) was associated with a 1-year survival of 70.4%, 3-year survival of 62.4%, 5-year survival of 54.1%, and 7-year survival of 47% (Fig. 2a) . ALBI grade also was stratified into a highrisk group (ALBI grade 3) and a low-risk group (grades 1 and 2), which revealed a distinct mortality rate between the two categories (p = 0.006) (Fig. 2b) .
For the 150 patients with HCC, ALBI grade was not associated with any survival difference neither for three ALBI group comparisons (p = 0.277) nor for comparison between ALBI grades 1 and 2 versus ALBI grade 3 (p = 0.149) (Fig. 3a, b) .
In contrast, when only patients without HCC were analyzed (n = 151), ALBI grade 3 was associated with a poorer overall survival than the low-risk groups (ALBI grades 1 and 2 as a single group) (p =0.038) (Fig. 4a, b) . There was no difference in survival rates when HCC patients were compared to patients without HCC (p = 0.186) (Fig. 5 ).
Patients were stratified into the three ALBI grade groups according to their HCV status. For both HCV-negative and HCV-positive recipients, ALBI grade 3 was associated with the worst overall survival. For the 192 HCV-positive recipients, there was a statistical difference in survival according to the three ALBI groups (p = 0.020) (Fig. 6 ). 
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For HCV-positive recipients, ALBI grade 3 was associated with a worst overall survival (Fig. 6a) . As compared to ALBI grades 1 and 2 group, ALBI grade 3 was associated with a 12% decrease in 1-year survival (77.6% vs. 89.5%), 15.5% decrease in 3-year survival (68.6% vs. 84.1), 17.6% decrease in 5-year survival (62.9 vs. 80.5%), and 20.9% decrease in 7-year survival (58.6% vs. 79.5%), (p = 0.012).
For the 86 non-HCV patients, there is a tendency toward an inferior survival for ALBI grade 3 patients. However, the difference did not reach statistical significance likely due to the small sample size of HCV-negative patients in this cohort (Fig. 6b) .
In this entire cohort, a calculated MELD score of 25 or higher (n = 43) was associated with a lower overall survival (1-, 3-, 5-, and 7-year survival of 71.8%, 60.6%, 54.4%, and 39.5%) versus 79.4%, 72.1%, 65.8%, and 63% of patients with a MELD score lower than 25 (p = 0.032) (Fig. 7a) .
The patients were stratified into four categories based on their ALBI grade (3 vs. 1 and 2 as a single group) and MELD score (lower than 25 vs. equal or higher than 25). Patients with both calculated ALBI grade 3 and calculated MELD score ≥ 25 (n = 24) had the lowest overall survival than the remaining 254 patients (1-, 3-, 5-, and 7-year survival of 54.2%, 40.6%, 35.5%, and 28.4 for ALBI grade 3 and MELD ≥ 25 vs. 80.9%, 73.4%, 65.2%, and 63.3% for the 254 remaining patients, p < 0.001) (Fig. 7b) . This cohort was further stratified into four groups by MELD score (lower than 25 vs. equal and higher than 25) and ALBI grade (ALBI grades 1 and 2 vs. ALBI grade 3). The two categories containing ALBI grade 3 recipients: ALBI grade 3 with MELD ≥ 25, (n = 14) and ALBI grade 3 with MELD < 25 (n = 67), displayed lower survival than the two categories containing ALBI grades 1 and 2 (p = 0.001) (Fig. 7c) . 
Discussion
LT has changed the natural history of end-stage liver disease. Optimization of graft-recipient match is a challenging task, since organ demand exceeds organ supply [12, 13] . Thus, refinements in prognostic metrics are important not only to the improvement of organ allocation, but also to avoid futility in LT [13] . Although MELD score has reduced waiting list mortality during the last decade, it is not a strong score for predicting post-LT mortality [13, 14] . As a matter of fact, some authors have proposed new scores (SOFT, BAR, SOLD) in order to estimate LT survival [15, 16] . However, these scores are based on a large number of variables including intraoperative ones, which are not available at the time of organ allocation [17] . It would be important to identify prognostic tools enabling preoperative prediction of LT outcomes. The ALBI score, a logarithmic score that involves only two variables (albumin and bilirubin), has been proposed as an objective method for estimating liver function and predicting survival in HCC patients [9, 18] . It has been demonstrated that the ALBI score is able to establish prognosis in HCC patients undergoing operative resection [19] , transarterial chemoembolization, and sorafenib treatment [10, 20, 21] . In addition, a worse ALBI grade (ALBI grade 3) has been associated with postoperative complications and mortality in hospitalized cirrhotic patients [22] . More recently, the preoperative predictive value of ALBI grade has also been reported in patients with gastric cancer, which suggests that there is a strong correlation between ALBI score and functional and/ or nutritional performance [23] . The present study was the first one to reveal ALBI score as negatively associated with post-LT outcomes. Specifically, multivariate analysis revealed ALBI grade 3 (ALBI grade score greater than − 1.39) is independently associated with a decreased overall post-LT survival in a cohort of recipients of 301 consecutive LTs. As compared to ALBI grade 1, an ALBI grade 3 is associated with a 2.67 death rate. As compared to the other ALBI grades (1 and 2 as a single group), ALBI grade 3 is associated with a 75% increase in overall mortality.
Albumin, BMI, and black race also were independently related to a worse overall post-transplant survival as evaluated by the Cox proportional hazards ratio method. As a continuous variable, a higher albumin was associated with a decreased mortality (HR 0.6, p value = 0.002 in the multivariate analysis). We then have performed a ROC curve with the three variables that were independently associated with a decreased survival (albumin, ALBI score, and BMI). In this ROC curve, the highest area under the curve (AUC) detected was for ALBI (0.629) versus 0.379 for albumin. Bilirubin was not associated with a decreased survival in the univariate analysis. However, as ROC curve revealed ALBI score as being a stronger predictor of mortality than albumin, the inclusion of bilirubin by performing the ALBI score seems to have played a synergistic effect in prediction of mortality.
The p value for ALBI grade for predicting 90-day mortality was equal to 0.1. Although the present study includes a total of 301 patients, it could have been underpowered to detect a statistical difference. Perhaps, an increase in the sample size would lead ALBI grade to become as statistical significant at predicting 90-day mortality.
For the subset of HCV-positive recipients (n = 192), ALBI grade 3 was associated with a worse overall survival. As compared to ALBI grades 1 and 2 group, ALBI grade 3 was associated with a 12% decrease in 1-year survival For the 86 HCV-negative recipients, the graphs display a visual difference that did not reach statistical significance. The difference did not reach statistical significance likely because of the small sample size for this category (Fig. 6b) .
In contrast to the previous results published in the literature that analyzed the ALBI grade classification in patients with HCC who were subjected to treatments other than LT [10, 18, 24, 25] , the present study revealed that ALBI grade had no prognostic role in patients who underwent LT for HCC. On the other hand, a high ALBI grade 3 was here associated with an increased mortality rate for LT receptors without HCC. In the present study, the cohort of non-HCC patients was composed of patients that were relatively sicker than the cohort of HCC patients (a mean MELD score of 21 for non-HCC patients vs. mean MELD score of 12 for HCC patients). For non-HCC patients, 45% (64/140) of all patients had a worse ALBI grade (ALBI grade 3). In contrast, only 20% (28/139) of HCC patients had a worse ALBI score (grade 3). This discrepancy between the ALBI grades in HCC and non-HCC patient groups-the latter cohort including more patients with ALBI grade 3-may have been responsible for the ability of ALBI grade to predict mortality in non-HCC (and not predict mortality in HCC patients). It is uncertain whether an increase in the sample (with additional patients in the subgroup of HCC patients with ALBI grade 3) would make ALBI grade as statistically significant for prediction of mortality in the HCC patient group. In a recent study, ALBI grade and ALBI and MELD scores have demonstrated similar efficiency in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS). MELD score was found to be a superior tool in estimating prognosis and mortality after the procedure [24] . However, there is not enough evidence to support prognostic superiority between the ALBI and MELD scores in patients with cirrhosis [22, 26] . The present study revealed a significant correlation between a high ALBI grade and mortality after LT, which was not observed with MELD score.
The results of this study corroborate previous ones, which have shown the limited role of the MELD score in predicting mortality after LT [14, 27] . MELD score was associated with a lower overall survival in the univariate analysis. Also, patients with a calculated MELD score of 25 or higher experienced a decrease in overall survival. However, MELD score was not independently associated with a decreased overall survival. Interestingly, ALBI grade 3 recipients possessing a MELD score of 25 or higher experienced marked decrease in overall survival. Thus, the association of ALBI grade 3 with MELD score 25 or higher was revealed as an additional negative prognostic score in this cohort. The combination of an ALBI grade 3 to a MELD score 25 or higher was associated with a 40.6% 3-year survival for the 24 patients possessing this combination in this cohort. It would be debatable whether LT should or not be offered to patients with a post-LT survival as low as revealed to this subset of patients.
The data presented in Fig. 7c revealed the best survivals seen in the ALBI grades 1 and 2 and high MELD group. The most likely reason for this finding is due to the small sample size in this patient group with low ALBI but high MELD score group (only 14 patients). Another possible explanation is that patients with relatively normal serum albumin and bilirubin (ALBI grades 1 or 2) but very high MELD scores (mostly driven by a high INR and/or high serum creatinine) had a much better post-transplant survival than patients with high MELD scores but low serum albumin. We believe that this finding reinforces the significance of ALBI as a better predictor of post-transplant mortality than the MELD score in this cohort.
One of the main limitations of this study is its retrospective nature. However, the study was based on a prospectively maintained data bank. For instance, MELD scores were available in 299 of the total 301 patients (99.3%). Also, ALBI grades were available for 279 of the total 301 patients (92.7%). Another potential limitation of this study is related to being a single-center analysis that may be subject to local or institutional issues which may have some influence on the external validity of the study. On the other hand, most of the medical and surgical team remained unchanged in this center in the majority of the transplants included in this cohort. This may strengthen the homogeneity of the population and the selection criteria, increasing the internal validity of this study. Another potential bias is that this study cohort was composed of a large proportion of HCV recipients in this cohort (70%). Thus, the study results should be interpreted with caution in a clinical context in which HCV patients do not predominate. However, HCV still is the leading indication for LT in the USA (33% of all LTs) and in several western countries [28, 29] . Thus, evaluating patients undergoing LT for HCV still is of utmost relevance.
In conclusion, this is the first study revealing the association of ALBI grade and decreased survival following LT. ALBI grade 3 may be used as a promising prognostic marker of post-LT mortality in recipients with end-stage liver disease not restricted to HCC. Further prospective studies with a larger number of patients are warranted to validate the findings of the present study, especially for non-HCV recipients. In addition, applicability of ALBI grade could be investigated in other clinical scenarios not restricted to oncological patients.
